Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia

Rachael Schulte1 | Ashley Hinson2 | Van Huynh3 | Erin H. Breese4 | Joanna Pierro5 | Seth Rotz6 | Benjamin A. Mixon7 | Jennifer L. McNeer8 | Michael J. Burke9 | Etan Orgel10

1Division of Pediatric Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
2Division of Pediatric Hematology and Oncology, Levine Children's Atrium Health, Charlotte, North Carolina, USA
3Division of Pediatric Oncology, University of California Irvine College of Medicine, CHOC Children's Hospital, Orange, California, USA
4Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center/University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
5Division of Pediatric Hematology/Oncology, NYU Grossman School of Medicine, Perlmutter Cancer Center, Hassenfeld Children’s Hospital at NYU Langone Health, New York, New York, USA
6Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
7Department of Pediatrics, University of Tennessee College of Medicine Chattanooga and Children’s Hospital at Erlanger, Chattanooga, Tennessee, USA
8Section of Pediatric Hematology, Oncology, and Stem Cell Transplant, University of Chicago Comer Children’s Hospital, Chicago, Illinois, USA
9Division of Pediatric Hematology/Oncology and Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
10Cancer and Blood Disease Institute, Children’s Hospital Los Angeles/University of Southern California, Los Angeles, California, USA

Correspondence: Etan Orgel, MD
MS, Children’s Hospital Los Angeles
Cancer and Blood Disease Institute
4650 Sunset Blvd, MS#54, Los Angeles
CA 90027, USA.
Email: eorgel@chla.usc.edu

Present address
Rachael Schulte, Center for Cancer and Blood Disorders, Riley Children’s Hospital/Indiana University School of Medicine, Indianapolis, Indiana, USA

Funding information
K12CA090625 (R.S.); 2KL2TR002457 (S.R.); UL1TR001855/UL1TR000130 (E.O.).

Abstract
Background: Pegaspargase (PEG-ASP) is an integral component of therapy for acute lymphoblastic leukemia (ALL) but is associated with hepatotoxicity that may delay or limit future therapy. Obese and adolescent and young adult (AYA) patients are at high risk. Levocarnitine has been described as potentially beneficial for the treatment or prevention of PEG-ASP-associated hepatotoxicity.

Methods: We collected data for patients age ≥10 years who received levocarnitine during induction therapy for ALL, compared to a similar patient cohort who did not receive levocarnitine. The primary endpoint was conjugated bilirubin (c.bili) >3 mg/dl. Secondary endpoints were transaminases >10× the upper limit of normal and any Grade ≥3 hepatotoxicity.
**INTRODUCTION**

Incorporation of asparaginase into treatment for acute lymphoblastic leukemia (ALL) has reduced relapse rates and improved survival for children. Recently, adoption of pediatric-inspired regimens inclusive of asparaginase has similarly improved survival for adolescent and young adult (AYA) patients with ALL. Unfortunately, the use of asparaginase-containing regimens in AYA patients is complicated by hepatotoxicity in up to 60% of patients, with obesity conferring additional increased risk. Histopathology of affected livers shows fatty infiltration lasting weeks to months with severity ranging from mild elevations of bilirubin and/or transaminases to fulminant liver failure. Asparaginase-induced hepatotoxicity results in significant morbidity, omission or dose reductions of chemotherapy, and in some cases, mortality. Thus, hepatotoxicity complicates the use of asparaginase in contemporary treatment regimens, particularly for vulnerable obese and/or AYA patients.

Traditional strategies to facilitate safe incorporation of asparaginase have focused on pharmacodynamic dosing intended to reduce drug exposure (e.g., reduced dose or dose-capping), but an emerging emphasis on hepatoprotective agents may offer alternative and/or complementary approaches. Within the liver, endogenous carnitine contributes to energy needs via fatty acid delivery and oxidation within the mitochondria and by buffering excess organic acids to maintain cellular viability. Levocarnitine and its analogues have demonstrated benefit to mitigate damage from other forms of drug-induced hepatotoxicity. Preclinical data and isolated case reports have led to increased off-label use of levocarnitine supplementation to potentially limit asparaginase-induced hepatotoxicity, including recommendations for its use in AYA populations. However, there is a paucity of clinical data demonstrating safety and efficacy of incorporating levocarnitine supplementation into ALL therapy. As a first step in addressing this critical knowledge gap, we conducted a study to investigate real-world data on the safety and efficacy of levocarnitine supplementation during ALL induction therapy.

**METHODS**

Demographic, diagnosis, and treatment information were collected on patients treated with a Children’s Oncology Group (COG)-style ALL induction regimen inclusive of pegylated L-asparaginase (PEG-ASP) (Table S1). No patients received other formulations of asparaginase during induction therapy. All patients with newly-diagnosed ALL who received levocarnitine during induction therapy were identified.

**Results:** Fifty-two patients received levocarnitine for prophylaxis (*n* = 29) or rescue (*n* = 32) of hepatotoxicity. Compared to 109 patients without levocarnitine, more patients receiving levocarnitine were obese and/or older and had significantly higher values for some hepatotoxicity markers at diagnosis and after PEG-ASP. Levocarnitine regimens varied widely; no adverse effects of levocarnitine were identified. Obesity and AYA status were associated with an increased risk of conjugated hyperbilirubinemia and severe transaminitis. Multivariable analysis identified a protective effect of levocarnitine on the development of c.bili >3 mg/dl (OR 0.12, *p* = 0.029). There was no difference between groups in CTCAE Grade ≥3 hepatotoxicity. C.bili >3 mg/dl during induction was associated with lower event-free survival.

**Conclusions:** This real-world data on levocarnitine supplementation during ALL induction highlights the risk of PEG-ASP-associated hepatotoxicity in obese and AYA patients, and hepatotoxicity’s potential impact on survival. Levocarnitine supplementation may be protective, but prospective studies are needed to confirm these findings.

**KEYWORDS**

adolescent, asparaginase, carnitine, chemical and drug-induced liver injury, precursor cell lymphoblastic leukemia-lymphoma, young adult
independently at each center and included for data capture (from 10 centers, treated 2014–2019). The indication for supplementation with levocarnitine, dosing regimens, and stopping criteria were determined by the treating clinicians and not standardized. Off-label use of levocarnitine for prophylaxis was nearly uniformly prescribed by providers to patients ≥10 years old, with analyses therefore limited to this group (one outlier patient <10 years old receiving levocarnitine prophylaxis for an anthracycline-sparing induction regimen was therefore excluded from analyses). This age cutoff is also in alignment with a recent study of risk factors for hepatotoxicity during ALL induction therapy.26 A second cohort was assembled from unselected and consecutively treated ALL patients ≥10 years old treated with the same COG induction chemotherapy without levocarnitine (from two centers, treated 2009–2019) (Table 1). Study endpoints were side effects from levocarnitine supplementation, incidence of hepatotoxicity, and disease response (minimal residual disease at end of induction [EOI MRD], event-free survival [EFS], and overall survival [OS]).

The primary hepatotoxicity endpoint was defined as conjugated bilirubin (c.bili) >3 mg/dl. This is the threshold in contemporary ALL protocols for dose modification of the hepatically metabolized induction chemotherapy agents (daunorubicin, vincristine). As minor elevations in aspartate (AST) and/or alanine aminotransferase (ALT) are common in ALL therapy, a secondary endpoint assessed severe transaminitis (defined for this study as >10× the upper limit of normal [ULN]; ULN for AST and ALT were set at 50 and 45 U/L, respectively). To enable inter-study comparisons, elevations in bilirubin and/or transaminitis were also graded using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 to describe Grade ≥3 hepatotoxicity. MRD was quantified by flow cytometry at COG-certified laboratories (MRD positive cutoff set at ≥0.01%)27; this endpoint was limited to patients with B-ALL. MRD was assessed at the end of the induction phase (EOI), and in those with EOI MRD ≥0.01%, at the end of the consolidation phase (EOC) following an additional ~8 weeks of cytotoxic chemotherapy. EFS was defined as time from diagnosis to last follow-up or first relapse, second malignancy, or death, and OS as time from diagnosis to death.

Levocarnitine supplementation was defined as “prophylaxis” when started anytime prior to PEG-ASP exposure.28 As the rationale for starting supplementation after PEG-ASP was not generally known (and was potentially due to early evidence or concerns for hepatotoxicity), levocarnitine started anytime following the first dose of PEG-ASP was classified as “rescue.” AYA age was classified as 15–39 years old at diagnosis.29

2.1 Statistical methods

Based on recent data for ALL induction hepatotoxicity,5,10,30 multivariable models for each hepatotoxicity endpoint were constructed using a preselected model inclusive of age, obesity, ethnicity, number of PEG-ASP doses in induction (1 or 2), and levocarnitine prophylaxis. Influence of sex was tested against this model using the likelihood ratio test (retained for p < 0.15). For clinical relevance, odds ratios were translated into the predicted probability for each hepatotoxicity endpoint and average marginal effects (AME)31 from incorporating levocarnitine prophylaxis were calculated, stratified by obesity and AYA age. A secondary analysis followed the same approach and examined levocarnitine supplementation started anytime after initiation of chemotherapy and prior to the onset of hepatotoxicity (c.bili >3 mg/dl). Logistic regression models for EOI MRD were constructed with prognostic covariables of presenting white blood cell count (WBC), age, obesity, and cytogenetic category. Impact of c.bili >3 mg/dl during induction and ethnicity was tested against the model (retained for p < 0.15). Cox multivariable models were constructed for EFS and OS using the same approach. Levocarnitine exposure (any) was then tested against each model for a potential association with MRD or survival.32 All statistical tests were two-sided and significance set at p < 0.05. Calculations were performed using STATA Statistical Software, SE Release 15.0 (StataCorp, LLC).

3 RESULTS

Data were collected on a total of 161 patients, 52 of whom received levocarnitine for prophylaxis (29/52 [56%]) or rescue (23/52 [44%]) during induction therapy. Of those patients receiving levocarnitine for rescue following administration of PEG-ASP, 10/23 (44%) began supplementation following elevated c.bili >3 mg/dl. Data for comparison were collected from 109 patients receiving induction chemotherapy without levocarnitine exposure. As shown in Table 1, patients receiving levocarnitine for prophylaxis were significantly more obese and older than patients without levocarnitine prophylaxis. Baseline hepatic function at diagnosis were more likely to show significant abnormalities from leukemic infiltration in those receiving levocarnitine supplementation (Table 2). Most patients received a single dose of PEG-ASP during induction therapy (154/161 [96%]) with several receiving two doses (7/161 [4%]). The PEG-ASP dose of 2500 IU/m² was “capped” at 3750 IU for 4% (6/161) of patients; the administered dose of PEG-ASP exceeded 3750 IU in the majority of patients (125/161 [77%]).
3.1 Levocarnitine supplementation

In those receiving levocarnitine prophylaxis, levocarnitine was started at a median of three days (range 1–30 days) prior to the first PEG-ASP dose, including one patient who received prolonged supplementation prior to PEG-ASP during treatment prophase. In the levocarnitine rescue group, levocarnitine was started a median of 18 days (range 0–43) following PEG-ASP, and, in the subset who developed c.bili >3 mg/dl, a median of 2 days (range 0–25) after c.bili exceeded >3 mg/dl. Levocarnitine dosing regimens varied widely, ranging from 330 to 1980 mg/dose PO or IV administered every 4–12 h (dose range 660–6400 mg/day); the most common dose was ~1000 mg TID.

### TABLE 1 Description of cohort

| Variable                        | Levocarnitine prophylaxis | Levocarnitine rescue | No levocarnitine | p-value |
|---------------------------------|---------------------------|----------------------|------------------|---------|
|                                 | N (%)                     | N (%)                | N (%)            |         |
| Cohort                          | 29 (100)                  | 23 (100)             | 109 (100)        |         |
| Age, years                      |                           |                      |                  |         |
| 10–14.9                         | 8 (28)                    | 3 (13)               | 57 (52)          | 0.001   |
| 15.0–39.9 (AYA)                 | 21 (72)                   | 20 (87)              | 52 (48)          | 0.001   |
| Median (range)                  | 17.0 (12–26.3)            | 18.8 (11.7–35)       | 14.7 (10–27.2)   | <0.001  |
| Sex                             |                           |                      |                  |         |
| Female                          | 8 (28)                    | 6 (26)               | 42 (39)          | 0.349   |
| Male                            | 21 (72)                   | 17 (74)              | 67 (61)          | 0.276   |
| Ethnicity                       |                           |                      |                  |         |
| Not Hispanic/Latinx             | 21 (72)                   | 13 (56)              | 29 (27)          | <0.001  |
| Hispanic/Latinx                 | 4 (14)                    | 10 (44)              | 70 (64)          | <0.001  |
| Unknown                         | 4 (14)                    | 0 (0)                | 10 (9)           | <0.001  |
| BMI categorya                   |                           |                      |                  |         |
| Not obese                       | 6 (21)                    | 10 (43)              | 76 (70)          | <0.001  |
| Obese                           | 23 (79)                   | 13 (57)              | 33 (30)          | <0.001  |
| BMI percentile                  |                           |                      |                  |         |
| Median (range)                  | 98.3 (18.1–99.8)          | 98.8 (19.3–99.7)     | 79.0 (0.2–99.8)  | 0.001   |
| Diagnosis                       |                           |                      |                  |         |
| B-ALL                           | 28 (97)                   | 21 (91)              | 89 (82)          | 0.105   |
| T-ALL                           | 1 (3)                     | 2 (9)                | 20 (18)          | 0.076   |
| Presenting WBCb                 |                           |                      |                  |         |
| <50 K/ul                        | 17 (59)                   | 13 (56)              | 76 (70)          | 0.280   |
| ≥50 K/ul                        | 12 (41)                   | 10 (44)              | 32 (30)          | 0.229   |
| FISH/Cytogeneticsc              |                           |                      |                  |         |
| Neutral                         | 11 (39)                   | 9 (43)               | 37 (42)          | 0.002   |
| Favorable                       | 1 (4)                     | 0 (0)                | 9 (10)           | 0.004   |
| Adverse                         | 16 (57)                   | 12 (57)              | 25 (28)          |         |
| Unknown                         | 0 (0)                     | 0 (0)                | 18 (20)          |         |

Abbreviations: ALL, acute lymphoblastic leukemia; BMI, body mass index; FISH, Fluorescence in situ hybridization; WBC, white blood cell count.

*aObesity categorized using age/sex norms for age 10–20 years and absolute BMI ≥30 for age ≥20 years (absolute BMI not included in median/range).

*bOne patient unknown.

*cFor B-ALL patients, classified using Children’s Oncology Group biology protocol AALL08B1 (modified to include Ph-like signatures as adverse prognostic markers).
(3000 mg/day) in 33/52 (64%). There was no significant difference in the mean daily dose delivered for prophylaxis vs rescue (2664 mg [SD 712] vs. 3,102 mg [SD 1387], p = 0.147). Levocarnitine supplementation (prophylaxis or rescue) was administered for a total of 4053 days (median 29 days/patient, range 1–872 days; one site treated for the duration of therapy). No side effects or early discontinuation were reported with levocarnitine supplementation.

| TABLE 2 | Selected laboratory values for each cohort |
| --- | --- | --- | --- | --- |
| | No levocarnitine | Levocarnitine prophylaxis | p-value<sup>a</sup> | Levocarnitine rescue | p-value<sup>a</sup> |
| At diagnosis | | | | | |
| AST, U/L median (range) | 39 (13–901) | 56 (15–708) | 0.109 | 53 (16–188) | 0.353 |
| ALT, U/L median (range) | 33 (6–840) | 86 (13–1,257) | <0.001 | 81 (6–314) | 0.005 |
| T.bili, mg/dl median (range) | 0.6 (0.1–4.4) | 0.8 (0.3–11.8) | 0.009 | 0.6 (0.2–2.8) | 0.249 |
| C.bili, mg/dl median, range | 0.4 (0.0–2.2) | 0.5 (0.0–7.3) | 0.335 | 0.2 (0.0–1.1) | 0.095 |
| Peak After PEG-ASP | | | | | |
| AST, U/L median (range) | 63 (11–6,789) | 89 (16–1,493) | 0.166 | 181 (34–6,297) | <0.001 |
| ALT, U/L median (range) | 140 (32–2,850) | 258 (20–862) | 0.031 | 431 (112–2,160) | <0.001 |
| T.bili, mg/dl median (range) | 1.5 (0.3–26.7) | 2.4 (0.5–20.8) | 0.015 | 6.4 (1.2–26.3) | <0.001 |
| C.bili, mg/dl median, range | 0.7 (0.0–20.7) | 1.1 (0.0–19.9) | 0.049 | 3.3 (0.0–21.8) | 0.001 |

<sup>a</sup>Significance in comparison to no levocarnitine cohort.

| TABLE 3 | Multivariable analysis of levocarnitine prophylaxis and hepatotoxicity endpoints |
| --- | --- | --- | --- | --- |
| Covariable | Conjugated bilirubin >3 mg/dl | AST or ALT >10× ULN |
| | OR | 95% CI | p-value<sup>a</sup> | OR | 95% CI | p-value<sup>a</sup> |
| Age | | | | | | |
| <15 years | Reference | | | Reference | | |
| ≥15 years | 4.27 | 1.22–14.93 | 0.023 | 3.77 | 0.95–14.96 | 0.059 |
| BMI Category<sup>b</sup> | | | | | | |
| Not obese | Reference | | | Reference | | |
| Obese | 6.14 | 1.88–20.05 | 0.003 | 5.02 | 1.25–20.18 | 0.023 |
| Ethnicity<sup>c</sup> | | | | | | |
| Not hispanic/Latinx | Reference | | | Reference | | |
| Hispanic/Latinx | 0.72 | 0.21–2.51 | 0.603 | 0.27 | 0.07–1.10 | 0.069 |
| PEG-ASP, # doses | | | | | | |
| One | Reference | | | Reference | | |
| Two | 2.65 | 0.24–29.41 | 0.427 | 2.62 | 0.24–28.90 | 0.431 |
| Levocarnitine suppl. | | | | | | |
| No levocarnitine | Reference | | | Reference | | |
| Prophylaxis | 0.13 | 0.02–0.81 | 0.029 | 0.34 | 0.07–1.73 | 0.194 |

Abbreviations: 95% CI, 95% Confidence Interval; BMI, body mass index; PEG-ASP, pegylated asparaginase; ULN, upper limit of normal.

<sup>a</sup>Logistic regression model, see methods; biologic sex was not significant in either model (p = 0.629 & p = 0.882, respectively).

<sup>b</sup>Obesity defined according to population norms for BMI in patients <20 years old (BMI percentile <95% vs. ≥95% and BMI <30 vs. ≥30 in patients ≥20 years old).

<sup>c</sup>Restricted to those with known ethnicity.
3.2  |  Prevention of hepatotoxicity

In the overall cohort, 34/161 (21%) developed c.bili >3 mg/dl, 27/161 (17%) developed study-defined severe transaminitis, and 16/161 (10%) developed both. CTCAE Grade ≥3 hepatotoxicity (transaminitis or hyperbilirubinemia) was reported in 83/161 (52%) of patients. More patients with obesity developed c.bili >3 mg/dl than those non-obese (21/69 [30%] vs. 13/92 [14%, p = 0.012] as did more AYA patients versus those younger (26/93 [28%] vs. 8/68 [12%, p = 0.013]). Among those with known ethnicity, the rate of c.bili >3 mg/dl was similar in those with self-reported Hispanic/Latinx ethnicity versus non-Hispanic/Latinx (16/84 [19%] vs. 25/63 [24%], p = 0.484). Similar trends were present for the secondary endpoint of severe transaminitis (obese vs. non-obese 17/69 [25%] vs. 10/92 [11%, p = 0.021; AYA vs. non-AYA 21/93 [23%] vs. 6/68 [9%, p = 0.031].

There was no significant difference in overall prevalence of c.bili >3 mg/dl or severe transaminitis in those receiving prophylaxis versus no prophylaxis (14% [4/29] vs. 16% [17/109], p = 0.810 and 21% [6/29] vs. 10% [11/109], p = 0.123). However, multivariable analysis accounting for the above at-risk populations demonstrated a significant protective effect of levocarnitine prophylaxis on risk for developing dose-limiting c.bili >3 mg/dl (odds ratio [OR] 0.12, 95% confidence interval [95% CI] 0.02–0.81, p = 0.029) but not for severe transaminitis (OR 0.34, 95% CI 0.07–1.73, p = 0.194) (Table 3). Analysis of AME showed incorporating levocarnitine prophylaxis into COG-style ALL induction therapy was predicted to significantly reduce the probability of developing c.bili >3 mg/dl (dy/dx −16.5%, 95% CI −0.27 to −0.06, p = 0.002) but not severe transaminitis (dy/dx −0.08%, 95% CI −0.19 to +0.03, p = 0.139). The predicted probability for each endpoint within high-risk population subsets (obesity, AYA) is shown in Figure 1. A trend was present for greater benefit from levocarnitine supplementation in those with older age at diagnosis (Figure 2). Secondary analyses reclassifying levocarnitine supplementation only as prior to or post-onset of hepatotoxicity irrespective of PEG-ASP timing showed similar trends (Table S2). Levocarnitine supplementation did not alter the risk for CTCAE grade ≥3 hepatotoxicity (OR 1.14, 95% CI 0.38–3.47, p = 0.812) (Table S3).

3.3  |  Treatment of hepatotoxicity

In patients who developed dose-limiting c.bili >3 mg/dl and received levocarnitine rescue following PEG-ASP exposure versus no levocarnitine supplementation (n=10 vs. n = 15), there was no significant difference in mean days to the start of the next treatment phase for those who survived induction (42.5 days [SD 9.9] vs. 40.3 days [SD 9.1], p = 0.573). Duration from c.bili >3 mg/dl until resolution <3 mg/dl was significantly longer in those selected to receive rescue versus no supplementation (12 days [IQR 24] vs. 3 days [IQR 12], p = 0.026). In the 8/10 patients starting levocarnitine only after c.bili >3 mg/dl, and who recovered from the toxicity, the median duration to resolution was 16.5 days (IQR 21). Induction deaths were rare (9/161 [6%]); among those who developed c.bili >3 mg/dl, there was no difference in the rate of induction deaths in those who received rescue versus no supplementation (3/13 [23%] vs. 3/17 [18%), p = 0.713). Peak levels of bilirubin and transaminases were significantly higher in the rescue cohort as compared to those without levocarnitine exposure (Table 2).

3.4  |  ALL disease response and survival

In the subset of 115 patients with B-ALL, known cytogenetics, and known end of induction (EOI) minimal residual disease (MRD), 47/115 (41%) received exogenous levocarnitine (prophylaxis 27/47 [57%, rescue 20/47 [43%]) and 68/115 (59%) did not. A higher prevalence of adverse cytogenetic features and fewer favorable genomic findings was present in levocarnitine supplemented patients (Table 1). MRD ≥0.01% was present at EOI in 44/115 (38%) and at EOC in 13/105 (12%). Levocarnitine supplementation was not associated with risk of MRD ≥0.01% (OR 1.68, 95% CI 0.62–4.58, p = 0.309) (Table 4). Analysis for the EOC MRD timepoint was limited by the lower prevalence of the persistent MRD positivity, but a multivariable analysis model inclusive only of cytogenetic risk and levocarnitine supplementation showed persistent influence of adverse cytogenetics (OR 5.2, 95% CI 1.29–20.63, p = 0.020) but no difference from levocarnitine supplementation (OR 0.68, 95% CI 0.19–2.37, p = 0.541). At a mean follow-up of 2.4 years (SD 2.1) for surviving patients, EFS and OS showed a significant difference for patients who developed c.bili >3 mg/dl during induction versus those who did not (3-year EFS 40 ± 11.2% vs. 77 ± 5.3%, p < 0.001; 3-year OS 58 ± 9.7% vs. 88 ± 4.0%, p < 0.001) (Figure SA,B). In multivariable analysis, incorporation of levocarnitine did not impact EFS or OS (Table S4).

4  |  DISCUSSION

This study highlights that patients who are obese and/or AYA constitute vulnerable populations at significantly higher risk for dose-limiting hepatotoxicity following treatment with PEG-ASP. Though acute mortality from
hepatotoxicity is rare, our findings also demonstrate a significant impact on survival from dose-limiting toxicity during induction therapy. To address these challenges, this is the first multicenter study to evaluate off-label usage of levocarnitine supplementation to prevent and/or rescue PEG-ASP-induced hepatotoxicity. Incorporation of levocarnitine was well tolerated with no associated adverse events reported in any patient and no indication of an adverse interaction with chemotherapy on disease response and survival. Despite the lack of a standardized approach to the incorporation of levocarnitine, a clear efficacy signal from levocarnitine prophylaxis was evident in patients at high risk for hepatotoxicity who received levocarnitine prophylaxis prior to PEG-ASP. Patients in this group had significantly higher values for ALT and total bilirubin prior to the start of therapy and higher peak values for ALT, total bilirubin, and c.bili following PEG-ASP (Table 2), likely reflecting their overall greater risk. However, in multivariable analysis accounting for these risk factors, levocarnitine prophylaxis reduced the odds of developing conjugated hyperbilirubinemia (Table 3). While this retrospective data is encouraging that levocarnitine may reduce rates of severe hepatotoxicity, the importance of a randomized controlled trial to validate the efficacy of levocarnitine prophylaxis cannot be understated.

Not surprisingly from use of an off-label medication, data from this study also highlights the wide variety in dosing regimens, starting/stopping criteria, and indications for levocarnitine supplementation in patients with ALL. Optimal dosing has yet to be determined. Most patients in this study were treated using 50–100 mg/kg/day, divided into two or three doses, with a maximum dose of 3 g/day, as previously recommended, and most patients were treated with oral supplementation. This regimen remains reasonable as intestinal absorption of levocarnitine is generally saturated at 1 gram/dose, repeated daily dosing of ≥2 grams/day increases total body carnitine, and with only ~1% of total body carnitine present in the liver, prolonged exposure is likely required to maximize hepatic concentrations. However, it is unknown if lower or less frequent dosing retains benefit, and conversely, whether higher dosing may be necessary in some situations.

**FIGURE 1** Probability of developing hepatotoxicity following PEG-ASP exposure. Multivariable models were constructed for each hepatotoxicity endpoint. Predicted probability of developing (A) conjugated bilirubinemia >3 mg/dl or (B) severe transaminitis (defined as aspartate or alanine aminotransferase >10× upper limit of normal) were calculated for patients with or without levocarnitine prophylaxis and stratified by at-risk populations (obesity, adolescent & young adult). *p < 0.05, **p < 0.01, n.s., not significant

**FIGURE 2** Average marginal effects from the incorporation of levocarnitine prophylaxis on the probability of conjugated bilirubin >3 mg/dl. From the multivariable logistic regression model for the endpoint of conjugated bilirubin >3 mg/dl, average marginal effects (AME) were calculated with associated 95% confidence intervals for the incorporation of levocarnitine prophylaxis.
Contrary to earlier anecdotal evidence,18,20,21,24 no clear benefit was found for levocarnitine rescue following severe hepatotoxicity. Patients developing severe hepatotoxicity did not rapidly recover and the duration of toxicity was similar to published non-supplemented cohorts.8,10 It is unknown if higher doses of levocarnitine or, alternatively, intravenous dosing to maximize delivery to the liver may have offered additional benefit. Thus, as opposed to the potential benefit from levocarnitine to prevent hepatotoxicity, no clear efficacy signal was present for levocarnitine rescue. A prospective trial will help further explore these continued knowledge gaps.

Understanding possible etiologies for susceptibility to hepatotoxicity, and particularly the contribution of pre-existing non-alcoholic fatty liver disease (NAFLD),34 will help to better guide levocarnitine use. Patients with NAFLD have altered mitochondrial respiratory chain function, including perturbations in carnitine shuttling.35 Oxidant stress from PEG-ASP exposure might exacerbate mitochondrial stress from NAFLD, resulting in progression to non-alcoholic steatohepatitis. This has been demonstrated in mice, where obesity causes activation of maladaptive pathways in hepatocytes in response to asparaginase-induced metabolic stress, leading to reduced ability of the cells to be rescued from this stress by normal pathways.36 NAFLD is common in the AYA population, affecting 10% of non-obese and 25%-50% of obese patients.37,38 Understanding the prevalence and impact of NAFLD on PEG-ASP toxicity and the potential role for levocarnitine supplementation is critical to reducing treatment morbidity from ALL induction therapy.

There are several limitations innate to this type of study. Given the off-label usage of levocarnitine, there was no standardized supplementation regimen. There was also likely selection bias in determining which patients were treated with levocarnitine as either prophylaxis or rescue. However, we would note this bias further supports evidence for efficacy since a benefit was seen even in those patients perceived to be at highest risk of hepatotoxicity. Older patients are at the higher risk for hyperbilirubinemia and transaminitis from induction therapy than younger patients11; thus, the benefits of levocarnitine may be even greater in an older AYA population. Conversely, data in our cohort for those <15 years of age was sparse but statistical modeling supported potential efficacy in this group. If levocarnitine proves effective in randomized trials in AYA patients, its role in preventing hepatotoxicity for younger at-risk patients should be explored. Moreover, the observed effect size from levocarnitine prophylaxis was sufficiently large to support a positive but anticipated smaller benefit in a future randomized trial. Additionally, in our study most patients were treated with a PEG-ASP dose of 2500 IU/m² regardless of age, and COG studies have only recently begun to incorporate lower dosing in older patients; this may have affected the rates of hepatotoxicity in our study, and differences between hepatotoxicity rates with different PEG-ASP dosing should be evaluated further in future studies.

Concurrent medication data was not collected in the rescue group, and synergy between levocarnitine and other vitamin complexes could not be assessed in this study. It will be crucial to collect this information in any forthcoming prospective trial of levocarnitine hepatoprotection. Finally, while raw laboratory data was collected, it is important to note that serial laboratory screening was not performed as it would be in the context of a prospective trial. Despite these limitations, given that levocarnitine was well-tolerated, with no evidence for chemotherapy interactions in vitro39 or influence on disease response in this study, our findings do not controvert current levocarnitine usage or recommendations as an intervention with limited risk and potential hepatic protection. Patients who are older or obese constitute an at-risk population warranting hepatoprotection. Thus, validating effective strategies to reduce hepatotoxicity is essential to improve the

---

TABLE 4  Multivariable analysis of levocarnitine supplementation and EOI MRD ≥0.01%

| Covariable       | OR   | 95% CI       | p-valuea |
|------------------|------|--------------|----------|
| Age, years       |      |              |          |
| <15 years        | Reference |      |          |
| ≥15 years        | 1.12 | 0.49–2.54    | 0.534    |
| BMI Categoryb    |      |              |          |
| Not obese        | Reference |      |          |
| Obese            | 1.67 | 0.74–3.77    | 0.215    |
| Presenting WBC   |      |              |          |
| <50 K/uL         | Reference |      |          |
| ≥50 K/uL         | 3.32 | 1.42–7.72    | 0.005    |
| FISH/Cytogeneticsc |     |             |          |
| Neutral          | Reference |      |          |
| Favorable        | 0.41 | 0.05–3.68    | 0.424    |
| Adverse          | 2.40 | 0.98–5.89    | 0.056    |
| Unknown          | 1.32 | 0.36–4.82    | 0.677    |
| Levocarnitine suppl. | 1.68 | 0.62–4.58    | 0.309    |

Abbreviations: BMI, body mass index; FISH, Fluorescence in situ hybridization; WBC, white blood cell count.

*aMultivariable logistic regression model constructed from prognostic factors and levocarnitine supplementation then tested against model, see methods.

*bObesity defined according to population norms for BMI in patients <20 years old (BMI percentile <95% vs. ≥95% and BMI ≥30 vs. <30 in patients ≥20 years old).

*cClassified as per Children’s Oncology Group biology protocol AALL08B1 (modified to include Ph-like signatures as adverse prognostic markers).
safe delivery of asparaginase-containing treatment regimens to AYA patients.

CONFLICT OF INTEREST
Advisory board, Jazz Pharmaceuticals (E.O., J.M.); Speaker’s bureau, Servier Pharmaceuticals (V.H.)

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Rachael Schulte https://orcid.org/0000-0002-7869-9099
Seth Rotz https://orcid.org/0000-0003-2896-1113
Etan Orgel https://orcid.org/0000-0002-1487-6818

REFERENCES
1. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91–01. Blood. 2001;97(5):1211-1218.
2. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526-534.
3. Stock W, Lugum SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548-1559.
4. Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375-380.
5. Christ TN, Stock W, Nenkel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018;24(4):299-308.
6. Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(7):554-563.
7. Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegaspargase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237-2253.
8. Burke PW, Aldoss I, Lunn MA, et al. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leuk Res. 2018;66:49-56.
9. Rausch CR, Marini BL, Benitez LL, et al. Peg blue pode risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(3):617-624.
10. Hashmi SK, Navai SA, Chambers TM, et al. Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(2):e28063.
11. Advani AS, Larsen E, Laumann K, et al. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021;5(2):504-512.
12. Pratt CB, Johnson WW. Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer. 1971;28(2):361-364.
13. Derman BA, Streck M, Wynne J, et al. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(3):614-622.
14. Patel B, Kirkwood AA, Dey A, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leuk. 2017;31(1):58-64.
15. Aldoss I, Douer D. How I treat the toxicities of pegaspargase in adults with acute lymphoblastic leukemia. Blood. 2020;135(13):987-995.
16. Brinkman K, Vrouenraets S, Kauffmann R, Weigel H, Fritzen J. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS. 2000;14(17):2801-2802.
17. Perrett J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother. 2010;44(7–8):1287-1293.
18. Schulte RR, Madiwale MV, Flower A, et al. Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. Leuk Lymphoma. 2018;59(10):2360-2368.
19. Al-Nawakil C, Willems L, Mauprivez C, et al. Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma. 2014;55(7):1670-1674.
20. Lu G, Karur V, Herrington JD, Walker MG. Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine. Proc (Bayl Univ Med Cent). 2016;29(1):46-47.
21. Blackman A, Boutin A, Shimansky A, Baker WJ, Forcello N. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature. J Oncol Pract. 2017;24(5):393-397.
22. Wieduwilt MJ, Goodman A, Jonas BA, et al. L-carnitine for pegylated-l-asparaginase induced hepatotoxicity. J Clin Oncol. 2017;35(15_suppl):e121626.
23. Rausch CR, Paul S, Marx KR, et al. L-carnitine and vitamin B complex for the treatment of pegaspargase-induced hyperbilirubinemia. Clin Lymphoma Myeloma Leuk. 2018;18(5):e191-e195.
24. Alshiekh- Nasany R, Douer D. L-carnitine for treatment of pegaspargase-induced hepatotoxicity. Acta Haematol. 2016;135(4):208-210.
25. Roesmann A, Afify M, Panse J, Eisert A, Steitz J, Tolba RH. L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers. Chemotherapy. 2013;59(3):167-175.
26. Denton CC, Rawlins YA, Oberley MJ, Bhojwani D, Orgel E. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatr Blood Cancer. 2018;65(3):e26891.
27. Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report...
28. Liu Y, Janke LJ, Li L, Relling MV. L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL/6 mouse model. *Leuk Lymphoma*. 2019;60(8):2088-2090.

29. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, LiveStrong Young Adult Alliance. Closing the gap; research and care imperatives for adolescents and young adults with cancer: a report of the Adolescent and Young Adult Oncology Progress Review Group. (https://planningcancer.gov/library/AYAO_PRG_Report_2006_FINAL.pdf, Last Accessed February 5, 2021). 2006.

30. Law JY, Dao BD, Le P, et al. Impact of body mass index and ethnicity on asparaginase toxicity in adult acute lymphoblastic leukemia patients. *J Clin Oncol*. 2015;33(15_suppl):e18051.

31. Onukwugha E, Bergtold J, Jain R. A primer on marginal effects–part I: theory and formulae. *Pharmacoeconomics*. 2015;33(1):25-30.

32. Cox DR, Snell EJ. *Analysis of Binary Data*. Vol vii. 2nd ed. Chapman and Hall; 1989:236.

33. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. *Ann N Y Acad Sci*. 2004;1033(1):30-41.

34. Schneider AL, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. *Obesity (Silver Spring)*. 2014;22(1):292-299.

35. Pérez-Carreras M, Del Hoyo P, Martín MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. *Hepatol*. 2003;38(4):999-1007.

36. Nikonorova IA, Al-Baghdadi RJ, Mirek ET, et al. Obesity challenges the hepatoprotective function of the integrated stress response to asparaginase exposure in mice. *J Biol Chem*. 2017;292(16):6786-6798.

37. Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016. *J Intern Med*. 2020;288(1):139-151.

38. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. *J Pediatr*. 2013;162(3):496-500.e1.

39. Sea JL, Orgel E, Chen T, et al. Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia. *Leuk Lymphoma*. 2020;61(2):420-428.

**SUPPORTING INFORMATION**
Additional Supporting Information may be found in the online version of the article at the publisher’s website.

---

**How to cite this article:** Schulte R, Hinson A, Huynh V, et al. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. *Cancer Med*. 2021;10:7551–7560. [https://doi.org/10.1002/cam4.4281](https://doi.org/10.1002/cam4.4281)